SAN DIEGO–(BUSINESS WIRE)–Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general management experience in roles across the healthcare, technology, and consumer products industries. Reeves will report to Chief Executive Officer, Francis deSouza.
Most recently, Reeves was Senior Vice President of Enterprise Marketing and General Manager of the Medical Services Global Business Unit at Cardinal Health, where she managed a rapidly growing portfolio of business with annual revenues in excess of $1 billion USD. Prior to Cardinal Health, Reeves held positions at Booz Allen Hamilton, AOL/Time Warner, Nationwide Insurance, and Scotts Miracle-Gro, among others.
“Kathryne has a strong track record of successfully building brands, bringing innovation to markets, deepening customer engagement, and growing revenue across a multitude of industries,” said Francis deSouza, Illumina’s Chief Executive Officer. “Her leadership will help us expand patient and physician awareness of the benefits of genomic testing, amplify the voice of our customers, and accelerate clinical adoption of genomics.”
“I am thrilled to be joining Illumina with the opportunity to lead a global organization of marketers that support one of the most innovative companies in technology,” said Reeves. “As Illumina progresses towards unlocking the power of the genome to improve human health, I’m excited to ensure that Illumina is deploying marketing effectively and strategically to accelerate adoption of sequencing in both research and clinical applications.”
Reeves is a member of the International Women’s Forum where she was a Leadership Fellow in 2017. She was named one of the Top Influential Women in Corporate America by the Savoy Network in 2016. Reeves holds a B.S. in Civil Engineering from Stanford University and an MBA from Harvard Business School.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are our ability to expand the adoption and use of genomics, especially in clinical settings, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.